Liaoning Chengda Biotechnology Co. Ltd. A (688739.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100004ZP2

Price
20.34 CNY
Market cap
8.47 bn CNY
P/E (2025)
64.27
P/S (2025)
6.09
Dividend yield
0.49 %
Net margin
9.48 %
Return on equity (ROE)
1.41 %
Return on assets (ROA)
1.35 %

Liaoning Chengda Biotechnology Co. Ltd. A financials

Fiscal year20242025
Revenue1.68 bn CNY1.39 bn CNY
Gross profit1.39 bn CNY1.10 bn CNY
Operating income453.56 m CNY196.98 m CNY
EBIT404.60 m CNY171.03 m CNY
Net income342.82 m CNY131.79 m CNY
Diluted EPS – continuing operations0.82 CNY0.32 CNY

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Liaoning Chengda Biotechnology Co. Ltd. A

Liaoning Chengda Biotechnology Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of vaccines in China and internationally. It offers inactivated Japanese encephalitis and SPEEDA-rabies vaccines. The company also develops rabies vaccine which is in new drug approval stage; influenza vaccine which is in new drug application stage; recombinant human papillomavirus 15-valent vaccine which is in Phase II clinical stage; and 13-valent pneumococcal polysaccharide conjugate, varicella, and meningococcal A, C, Y and W-135 conjugate vaccines which are in Phase I clinical stage. In addition, it is involved in the development of high-dose influenzae vaccine which is in CT approval stage; and vaccines in pre-clinical study stage, including 20-valent pneumococcal polysaccharide conjugate, recombinant zoster, multivalent HFMD, serogroup B meningococcal outer membrane vesicle, and rabies monoclonal antibody. The company was formerly known as Liaoning Chengda Biological Technology Limited Company and changed its name to Liaoning Chengda Biotechnology Co., Ltd. in November 2010. Liaoning Chengda Biotechnology Co., Ltd. was incorporated in 2002 and is headquartered in Shenyang, China. The company operates as a subsidiary of Liaoning Cheng Da Co., Ltd.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.